Douglas B Johnson
Overview
Explore the profile of Douglas B Johnson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
331
Citations
19201
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fletcher K, Goodman R, Lawless A, Woodford R, Faak F, Tipirneni A, et al.
JAMA Dermatol
. 2025 Mar;
PMID: 40072456
No abstract available.
2.
Davis Puente A, Davis A, Johnson D, Bastarache J
BMJ Open Respir Res
. 2025 Mar;
10(1).
PMID: 40042935
Introduction: Immune checkpoint inhibitors (ICI) have improved outcomes for patients with many malignancies. However, these treatments are associated with immune-related adverse events, including pulmonary toxicity (pneumonitis). Pneumonitis is associated with...
3.
Nassar A, Abou Alaiwi S, El Zarif T, Denu R, Macaron W, Abdel-Wahab N, et al.
J Immunother Cancer
. 2025 Mar;
13(3).
PMID: 40032601
Background: Data on the safety profiles and clinical outcomes of patients with solid tumors and cardiac metastasis treated with immune checkpoint inhibitors (ICIs) are limited. Methods: This is an international...
4.
Holowatyj A, Overman M, Votanopoulos K, Lowy A, Wagner P, Washington M, et al.
Nat Rev Cancer
. 2025 Feb;
PMID: 39979656
Tumours of the appendix - a vestigial digestive organ attached to the colon - are rare. Although we estimate that around 3,000 new appendiceal cancer cases are diagnosed annually in...
5.
Schiantarelli J, Benamar M, Park J, Sax H, Oliveira G, Bosma-Moody A, et al.
Cancer Cell
. 2025 Feb;
43(2):308-316.e6.
PMID: 39933900
Although some patients with metastatic melanoma experience durable responses to immune checkpoint inhibitors (ICIs), most exhibit intrinsic or acquired resistance to these therapies. Here, we compare somatic genomic profiles from...
6.
Dankner M, Rousselle E, Petrecca S, Fabi F, Nowakowski A, Lazaratos A, et al.
JCO Precis Oncol
. 2025 Jan;
9:e2400199.
PMID: 39869838
Purpose: MAP2K1/MEK1 mutations are potentially actionable drivers in cancer. MAP2K1 mutations have been functionally classified into three groups according to their dependency on upstream RAS/RAF signaling. However, the clinical efficacy...
7.
Kankaria R, Johnson D
Oncologist
. 2025 Jan;
30(1).
PMID: 39832128
Immune checkpoint inhibitors (ICIs) have advanced the treatment of metastatic melanoma. However, some patients develop ICI-associated toxicities like hepatitis (ie, immune-mediated hepatitis; IMH). Although these toxicities usually resolve with steroids,...
8.
Handel E, McKeown J, Wei J, Kankaria R, Burnette H, Johnson D, et al.
Eur J Cancer
. 2024 Dec;
215:115171.
PMID: 39667250
Immune checkpoint inhibitors (ICI) can achieve durable responses in patients with advanced melanoma, and results from clinical trials suggest cure may be possible for a subset of patients. Despite clinical...
9.
Dimitriou F, Orloff M, Koch Hein E, Cheng P, Hughes I, Simeone E, et al.
Eur J Cancer
. 2024 Dec;
214:115161.
PMID: 39647344
Background: Metastatic uveal melanoma (mUM) is rare. Immune checkpoint inhibitors (ICIs) have shown modest efficacy in mUM. Tebentafusp prolonged overall survival (OS) in a phase 3 study. We aimed to...
10.
Lurain K, El Zarif T, Ramaswami R, Nassar A, Adib E, Abdel-Wahab N, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Nov;
24(12):873.
PMID: 39603773
No abstract available.